NEW YORK, Jan. 24, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Universal Health Services, Inc. securities (NYSE:UHS) from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”) of the important February 21, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Universal Health investors under the federal securities laws.
To join the Universal Health class action, go to http://www.rosenlegal.com/cases-1008.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not upon the medical necessity of the patient; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to ensure the maximum payment for its services; (3) as a result, Universal Health’s revenues from inpatient care relied on unsustainable practices; (4) in turn, Universal Health lacked effective internal control concerning its practices and policies of admitting patients; and (5) as a result, Universal Health’s public statements were materially false and misleading at all relevant times. On December 7, 2016, Buzzfeed published an investigative story on Universal Health alleging, among other things, that Universal Health put profits ahead of people. On this news, shares of Universal Health fell $15.01 per share, or nearly 12%, from its previous closing price to close at $111.36 per share on December 7, 2016, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 21, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1008.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Italy Fines Apple €98.6 Million Over App Store Dominance
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



